A Phase I Study of Single and Multiple Doses of HS-20136-2 Injection in Healthy or Obese Participants

Sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Study ID
NCT07716241
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • HS-20136-2 — DRUG
    Single-dose pen of HS-20136-2 injection solution
  • Placebo — DRUG
    Single-dose of placebo
  • HS-20136-2 — DRUG
    multi-dose pen of HS-20136-2 injection solution
  • placebo — DRUG
    multi-dose of placebo

Study Details

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of HS-20136-2 injection in healthy/obese participants.

Key Dates

First listed
Jul 21, 2026
Start date
Sep 22, 2026
Status verified
Jul 2026
Primary completion
May 14, 2027
Completion
May 14, 2027

Study Design

Enrollment
92 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: HS-20136-2
    Subcutaneous injection once，Subcutaneous injection three times
  • Placebo Comparator: placebo
    Subcutaneous injection once，Subcutaneous injection three times

Primary Outcome Measure

Number of Adverse Events [ Time Frame: Start of Treatment to end of study (approximately 57 days or 112 days) ]

Central Contacts

Find similar trials

Nationwide
Obesity / overweight trialsEndocrinology trialsMetabolic health trialsWeight loss trials

Related Studies